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Clinical pain is a serious public health issue. Treatment of pain-related suffering requires knowl-
edge of howpain signals are initially interpreted and subsequently transmitted and perpetuated.
This review article is one of three reviews in this issue ofNeuron that address our understanding
of the pain process and possible solutions to the problem from both cellular- and systems-level
viewpoints.
The electrophysiological properties of peripheral neurons activated by noxious stimuli, the primary
afferent nociceptors, have been investigated intensively, and our knowledge about the molecular
basis of transducers for noxious stimuli has increased greatly. In contrast, understanding of the in-
tracellular signaling mechanisms regulating nociceptor sensitization downstream of ligand binding
to the receptors is still at a relatively nascent stage. After outlining the initiated signaling cascades,
we discuss the emerging plasticity within these cascades and the importance of subcellular compart-
mentalization. In addition, the recently realized importance of functional interactions with the extra-
cellular matrix, cytoskeleton, intracellular organelles such as mitochondria, and sex hormones will
be introduced. This burgeoning literature establishes new cellular features crucial for the function
of nociceptive neurons and argues that additional focus should be placed on understanding the
complex integration of cellular events that make up the ‘‘cell biology of pain.’’Introduction
From prokaryotes to higher eukaryotes, the complexity of
cellular organization expandedgreatly. Cell compartments
such as membrane-enclosed organelles and protein
clusters at functional sites evolved. In higher eukaryotes,
a multitude of specialized cells interact in a time- and
tissue-dependent manner. This increase in organizational
complexity is the necessary basis for the ability to integrate
increasing quantities and qualities of information about
the external as well as internal condition of the organism.
Sensory neurons in vertebrates connect peripheral tis-
sues with the central nervous system, occupying a partic-
ularly prominent position in acute information reception,
transduction, and integration. But they also show the po-
tential to undergo long-lasting plastic changes. This plas-
ticity, often in the form of sensitization, memory for prior
injury, or desensitization, can be beneficial in the case of
avoidance of physical stimulation of injured tissue. In con-
trast, in cases of chronic inflammatory or neuropathic
pain, these changes produce an often disabling burden
on the organism.
Nociceptive neuron sensitivity is modulated by a large
variety of mediators in the extracellular space. These me-
diators activate a large number of receptor classes, which
in turn activate a plethora of signaling cascades (Julius
and Basbaum, 2001; Lewin et al., 2004; Scholz andWoolf,2002; Figure 1). How this multitude of cascades mediates
nociceptor sensitization and pain is only beginning to be
understood. As function relies upon structure, investiga-
tion of the cellular components involved in this process
has greatly enhanced the understanding of nociceptive
mechanisms and their modulation and opened surprising
new fields of research.
We review the existing data establishing the importance
of classical intracellular signaling components in inflam-
matory and neuropathic pain. Often in nociceptive neu-
rons the cascade-initiating receptor(s) has not been fully
characterized. Thus, we sort data according to the core
components of the respective signaling cascade. This
also avoids confusion, as signaling pathways can be acti-
vated and/or modulated by more than one receptor. This
overview is then followed by the introduction of two com-
plementary models that might integrate this data. The
models intrinsic logic highlights the need for furthering
our understanding of the basic cell-biological mecha-
nisms that impact nociceptor signaling. And indeed, as
exemplified by pioneering works, the complex cellular
organization of nociceptive neurons (e.g., subcellular
compartmentalization, signaling cascade plasticity, extra-
cellular matrix components, the cytoskeleton, intracellular
organelles, and sex hormones) is essential for its function.
We will argue that a thorough investigation of theseNeuron 55, August 2, 2007 ª2007 Elsevier Inc. 365
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essential in order to fully understand how nociceptive cas-
cades function. Additionally, by elucidating new compo-
nents of this signaling cascade, such basic cell-biological
research should also help to identify potential new thera-
peutic targets for management of pain.
Nociceptor Signaling Pathway Components
cAMP and Protein Kinase A (PKA)
The first cellular second messenger discovered, cAMP,
was also the first implicated in pain and nociceptor sensi-
tization. Indeed, intradermal injection of membrane-
permeable cAMP analogs (Ferreira et al., 1990; Taiwo
et al., 1989) or the adenylyl cyclase activator forskolin
(Taiwo and Levine, 1991), produce robust sensitization to-
ward physical stimuli (hyperalgesia) and sensitization of
nociceptive fibers (Kress et al., 1996). Inflammatory medi-
ators such as prostaglandins result in increased intracellu-
lar cAMP and lead to hyperalgesia, which can be blocked
by the inactive cAMP analog, Rp-cAMP (Taiwo and Lev-
ine, 1991). The inflammation-induced increase in cAMP
also induces cellular correlates of pain such as increased
evoked transmitter release (Hingtgen et al., 1995) and
modulates voltage (England et al., 1996; Gold et al.,
1998) and ligand-gated ion channels important in pain
(Lopshire and Nicol, 1998; Pitchford and Levine, 1991).
Not only the onset but also the duration of hyperalgesia
is dependent on continuously elevated cAMP levels.
Thus, Rp-cAMP reduces hyperalgesia even if injected af-
ter hyperalgesia is already established (Aley and Levine,
1999; Taiwo and Levine, 1991). The intracellular cAMP
Figure 1. Signaling Components in Nociceptors
A large number of extracellular mediators modulate nociception. They
act through several receptor classes. Thereby, a plethora of intracellu-
lar signaling cascades is initiated. So far, research has concentrated
on verifying the involvement of core components of these pathways
mostly neglecting the identification of upstream aswell as downstream
signaling components. Only few downstream effectors (red ovals)
such as ion channels have been identified, the discussion of which is
beyond the scope of this review. As none of the components charac-
terized so far fully explains the process of sensitization, further cellular
components have to be investigated.366 Neuron 55, August 2, 2007 ª2007 Elsevier Inc.concentration in nociceptive neurons can be reduced by
activation of endogenous m-, d-, and k-opioid receptors,
which may be, in part, responsible for the peripheral
antinociceptive actions of morphine and other opioids
(Aley and Levine, 1997; Collier and Roy, 1974; Ferreira
and Nakamura, 1979; Stein et al., 1989). Long-term expo-
sure to opioids results in desensitization of the opioid
receptors and compensatory production of cAMP accom-
panied by loss of the antinociceptive effect of opioids
(Nestler, 2004).
cAMP signaling is widely held to be synonymous with
the activity of its binding partner, protein kinase A (PKA).
Pharmacological as well as genetic inhibition of PKA, re-
sults in a reduction of inflammatory mediator-induced
hyperalgesic behavior (Aley and Levine, 1999; Malmberg
et al., 1997), in reduced nociceptor discharge (Cui and
Nicol, 1995; Zhang et al., 2002a), as well as in attenuated
stimulus-induced peptide release (Oshita et al., 2005).
While the exact mechanisms of these PKA-mediated
effects are not fully understood, mutation of PKA phos-
phorylation sites on effector ion channels such as the pri-
mary afferent nociceptor specific, tetrodotoxin-resistant
sodium channel, NaV1.8 (TTX-R INa) (Fitzgerald et al.,
1999) and the ligand-gated ion channel TRPV1 (Bhave
et al., 2002) results in ablation of channel modulation by
PKA.
It has recently become clear that cAMP can also acti-
vate molecules other than PKA such as calcium channels
(reviewed by Kaupp and Seifert, 2002) and the GDP/GTP
exchange factor Epac (de Rooij et al., 1998; Kawasaki
et al., 1998; see discussion below). Therefore, some of
the established data on cAMP signaling pathways in noci-
ceptor sensitization must also take these additional
targets into consideration (Hucho et al., 2005). While
cAMP/PKA signaling is important for inflammatory hyper-
algesia, it is also clear that other second messenger path-
ways play critical roles in this process.
Protein Kinase C (PKC)
There is an extensive literature documenting a role of
PKC in nociceptor activation as well as sensitization.
PKC activating phorbol esters and inflammatory media-
tors cause long-lasting nociceptive behaviors (Souza
et al., 2002) and depolarize as well as activate nociceptors
(Burgess et al., 1989b; Dray et al., 1988; Rang and Ritchie,
1988).
Also, sensitization of nociceptors can be induced in
a PKC dependent manner, as measured by thermal and
mechanical hyperalgesia (Souza et al., 2002), mechani-
cally induced nociceptor activity in knee joint afferents
(Schepelmann et al., 1993), thermally induced secretion
of neuropeptides from the peripheral terminals of afferents
(Cesare et al., 1999; Kessler et al., 1999), as well as
increase of TTX-R INa in DRG neurons (Cesare and
McNaughton, 1996; Gold et al., 1996). Treatment of
TRPV1 expressing cells with phorbol esters lowers the
heat-threshold of TRPV1 below body temperature and
sensitizes TRPV1 expressing cells to stimulation by cap-
saicin (Crandall et al., 2002; Premkumar and Ahern,
Neuron
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rect phosphorylation (Bhave et al., 2003; Mandadi et al.,
2006; Numazaki et al., 2002) leading to, among other
changes, PKC-dependent insertion of TRPV1 channels
into the plasma membrane (Morenilla-Palao et al., 2004;
Van Buren et al., 2005).
At least six PKC isoforms (a, bI, bII, d, 3, z) have been
detected in DRG neurons. But only PKC3, a member of
the calcium-independent novel PKCs, has been shown
to be activated by the inflammatory mediators bradykinin,
epinephrine, carrageenan, tumor necrosis factor alpha
(TNFa), and the protease-activated receptor (PAR2) and
to mediate sensitization to mechanical and thermal stimuli
(Amadesi et al., 2006; Cesare et al., 1999; Khasar et al.,
1999a; Olah et al., 2002; Parada et al., 2003a). In a PKC3
knockout mouse, the basal threshold to mechanical as
well as thermal stimulation was unchanged. In contrast,
sensitization in response to inflammatory mediator treat-
ment was much reduced (Khasar et al., 1999b). Indeed,
sensitization of the nociceptor specific TTX-R INa was
dependent on PKC3 activity (Khasar et al., 1999b), and
enhanced activity of another ion channel important in
inflammatory pain, TRPV1, was shown to require direct
phosphorylation of TRPV1 by PKC3 (Bhave et al., 2003;
Mandadi et al., 2006; Numazaki et al., 2002).
Beyond inflammatory mediator-induced sensitization
PKC3 is involved in various models of neuropathic pain,
such as that associated with diabetes (Joseph and Levine,
2003b), chronic alcoholism (Dina et al., 2000), and cancer
chemotherapy (Dina et al., 2001b; Joseph and Levine,
2003a). In addition, PKC3 activity widens the generally ac-
cepted dichotomy of naive and sensitized nociceptors by
defining the novel ‘‘primed state’’ (see discussion below
and Figure 3). Interestingly, PKC3 signaling in primary af-
ferent nociceptors was found to depend on cytoskeleton
and cell membrane microdomains (expanded upon
below), exemplifying the need to investigate other cellular
aspects than electrophysiological properties and kinase
activation states for nociceptor sensitization.
Mitogen-Activated Protein Kinases (MAPK)
Mitogen-activated protein kinases (MAPKs) have also
recently been implicated in nociceptor sensitization asso-
ciated with inflammation and peripheral neuropathy. Acti-
vation of ERK1/2 by b2-adrenergic agonists contributes to
mechanical hyperalgesia (Aley et al., 2001). In nocicep-
tors, ERK is also activated by NGF (Averill et al., 2001;
Delcroix et al., 2003; Malik-Hall et al., 2005), capsaicin,
electrical stimulation (Dai et al., 2002; Ji et al., 1999),
Freund’s adjuvant (Obata et al., 2003), and nerve transec-
tion (Obata et al., 2003).
MAPK p38 is activated in response to peripheral inflam-
mation (Ji et al., 2002), and activation of TRPV1 leads to
p38-dependent hyperalgesia (Mizushima et al., 2005). In-
flammation, axotomy, and spinal nerve ligation similarly
activate p38 in spinal cord and DRG neurons, contributing
to neuropathic pain (Jin et al., 2003; Kim et al., 2002). In the
spinal nerve ligation model of painful peripheral neuropa-
thy, TNFa was central to p38 phosphorylation and me-chanical hyperalgesia (Jin and Gereau, 2006; Pollock
et al., 2002; Schafers et al., 2003). But also receptor acti-
vation and retrograde transport of locally produced NGF
resulted in p38 activation leading to increased expression
of TRPV1 (Ji et al., 2002).
Additional members of the MAPK family, c-Jun amino-
terminal kinase 1 (JNK) and ERK5, are also implicated in
nociception. Nerve transection results in chronic activa-
tion of JNK in DRGs in a process that appears to require
retrograde transport (Kenney and Kocsis, 1998), and
TNFa induces activation of JNK in cultured sensory neu-
rons (Pollock et al., 2002).
Nitric Oxide (NO)
In addition to the kinases, reviewed above, the second
messenger nitric oxide (NO) contributes to induction of
pain and sensitization in humans (Holthusen and Arndt,
1994), rats (Aley et al., 1998; Chen and Levine, 1999), as
well as Aplysia (Lewin and Walters, 1999). The NO-pro-
ducing enzyme, nitric oxide synthase (NOS), was localized
immunohistochemically in small- and medium-diameter,
nociceptive DRG neurons in rat and monkey (Zhang
et al., 1993). NOS expression is prominent during develop-
ment and after nerve lesion (Majewski et al., 1995; Qian
et al., 1996). Its immunoreactivity is increased in DRG neu-
rons by noxious irritants (Vizzard et al., 1995, 1996) as well
as nerve injury (Choi et al., 1996; Steel et al., 1994; Zhang
et al., 1993). Also, production of the downstream effector
of NO, cGMP, sharply increases in response to exposure
to inflammatory mediators (Burgess et al., 1989a). In turn,
inhibition of NOS suppresses activity in dorsal roots orig-
inating from sciatic neuromas (Wiesenfeld-Hallin et al.,
1993) and reduces thermal hyperalgesia established by
chronic constriction injury or hindpaw inflammation
(Moore et al., 1993; Thomas et al., 1996). Also, in cultured
DRG neurons, the Prostaglandin E2 (PGE2)-induced
increase of TTX-R INa was partially suppressed by NOS
inhibitors (Aley et al., 1998).
However, unlike the other second messengers, NO has
the potential to induce opposing effects. Thus, antinoci-
ceptive effects of NO are also reported (Duarte et al.,
1992; Kawabata et al., 1994), potentially due to differential
dosing (Kawabata et al., 1994) or depth of injection into the
animals skin (Vivancos et al., 2003).
The exact function and interrelationship of the different
second messengers discussed above as well as others
(e.g., calcium influx, ceramide, caspases, BH4,.) in no-
ciceptor signaling remains to be established. Establish-
ment of these relationships must also take into account
the extent to which these signaling components are acti-
vated in the same cell and additionally whether they are
activated within the same or distinct cellular compart-
ments. Below, we expand upon these points in an effort
to highlight the importance of taking a broader cell-biolog-
ical approach to nociceptor signaling in order to under-
stand both the physiological and pathophysiological con-
sequences that can arise via the plethora of signaling
cascades potentially activated in response to noxious
stimuli.Neuron 55, August 2, 2007 ª2007 Elsevier Inc. 367
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Signaling Models
The observed multitude of signaling pathways,
all of which lead to the induction of hyperalge-
sia, raises the question of the relationships
between the signaling cascades. Two comple-
mentary models have to be considered: (1) the
signaling components define parallel path-
ways, leading to the modification of distinct ef-
fector molecules (orange arrows, red ovals,
left). Alternatively, (2) at least partial con-
vergence occurs, leading necessarily to the
formation of a nociceptive module (orange
arrows, red area, right). Currently, data do not
falsify any of the two. Detailed analysis of the
signaling pathways, their downstream targets,
as well as modulatory sites in the primary affer-
ent nociceptive neuron is required.A Cell-Biological View of Nociceptor Signaling
Parallel versus Convergent Signaling
The studies reviewed above have established the involve-
ment of selected classical signaling molecules in sensiti-
zation of primary afferent nociceptors (Figure 1). But
even with a fairly solid understanding of the contribution
of a number of signaling components a synthesis of the
pathways mediating sensitization is lacking. Having
many stimuli all leading to sensitization, a priori two com-
plementary models of signaling have to be considered: (1)
the signals resulting in nociceptor sensitization are sepa-
rate and involve distinct and nonoverlapping signaling
components which modify separate effector molecules
(Figure 2, left). (2) The signal cascades are not separate,
i.e., the initiated cascades converge (partially or com-
pletely) (Figure 2, right). Both of these models bear impor-
tant implications. If the signaling is parallel, the current
phenotypic distinction between mechanical and thermal
hyperalgesia would have to be further differentiated, as
necessarily the involvement of distinct effector molecules
defines also mechanistically distinct phenotypes. On the
other hand, if convergence occurs, a common ‘‘nocicep-
tion module’’ would be defined with intriguing possibilities
for novel therapeutic interventions. But, illustrating the in-
sufficiency of the current knowledge about nociceptive
signaling pathways, the important and very basic ques-
tion, which of these two complementary models can be
ruled out, has yet to be answered.
Model to Be Tested on the Level
of Signaling Cascades
At the level of the initial stimulus, noxious physical stimuli
and changes in the immediate tissue environment act on
the nociceptors. As reviewed by others (Julius and Bas-
baum, 2001; Scholz and Woolf, 2002), the concentration
of neurotransmitters, growth factors, hormones, fatty
acid derivates, neuropeptides, cytokines, ATP, and pro-
tons are altered, resulting in what has been referred to
as an inflammatory soup. As eachmediator has the poten-
tial to individually modulate sensitization, convergence at
the stimulus level seems unlikely. Also, evidence for con-
vergence at the receptor level has, so far, not emerged, as
a wide variety of receptors from classes as different as G
protein-coupled receptors, receptor tyrosine kinases,368 Neuron 55, August 2, 2007 ª2007 Elsevier Inc.TNF-family receptors, ligand-gated ion channels, and
cytoplasmic/nuclear steroid hormone receptors are
activated (Figure 2).
But the models have to be tested on two successive
levels of signal transmission: the use of distinct versus
convergent neuronal subpopulations and of distinct
versus convergent intracellular signaling pathways. Po-
tentially, separate stimuli can act on separate neurons,
as, e.g., the respective receptors are not expressed ubiq-
uitously. And, indeed, nociceptive neurons of varying sub-
types are differentiated by histological, electrophysiologi-
cal, and molecular characteristics (Julius and Basbaum,
2001). How these neurons are interconnected, how other
neurons such as the peripheral sympathetic nervous sys-
tem and central interneurons modulate them, as well as to
what extent they innervate the same or distinct areas in the
spinal cord is beyond the scope of this review. We would
only like to note here, that while the number of nociceptive
neuron subtypes is increasing, most nociceptors are, nev-
ertheless, described as polymodal, i.e., responding to
multiple kinds of stimuli (Lewin and Moshourab, 2004).
Therefore, the question of parallel versus convergent use
of nociceptive neuron subtypes remains open. Some of
these important unanswered questions can be addressed
by studying the next level, the intracellular signaling.
There, to validate either of the two models, one has to fol-
low the so-far-identified signaling components all the way
down to the effector molecules. Doing this for more than
one cascade, it will emerge, if the cascades and/or effec-
tors are separate or not. Keeping markers for nociceptive
subtypes included, will indicate also the use of parallel
versus convergent neuronal subtypes.
Investigations to test the complementary models for
validity has to consider new aspects of importance
much beyond the classical signaling components dis-
cussed so far, which are established by recently emerging
results discussed in the following sections.
Variability of Receptor Signal-Cascade Coupling
In other cellular systems, it is known that stimuli which lead
to similar net effects often activate the same intracellular
signaling cascades (e.g., receptor tyrosine kinases in Dro-
sophila eye development [Freeman, 1996]). In nociceptive
neurons, do extracellular mediators, which activate the
Neuron
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mechanism? Both epinephrine and PGE2 use as-coupled
G protein receptors (GPCRs). However, while epinephrine
hyperalgesia involves PKA, PKC3, and ERK1/2, PGE2-
induced hyperalgesia is PKA dependent only (Aley et al.,
2001; Hucho et al., 2005; Khasar et al., 1999a). Therefore,
stimulating a similar receptor/mediator module such as
GPCRs coupled to as does not necessarily result in the
stimulation of the same downstream events. Core compo-
nents such as PKC3 and ERK1/2 can be excluded from
the sensitization process even though in both cases as is
activated.
Selective Activation of Signaling Pathways
At the moment, it remains unclear what determines the
use of the varying signaling pathways in nociceptive neu-
rons. Increasingly, the importance of subcellular cluster-
ing and signaling ‘‘hub’’ formation is being investigated.
One such class of compartments are lipid rafts. They are
membrane patches enriched in sphingomyelin- and cho-
lesterol-based lipids, accumulating a large number of pro-
teins (Ostrom and Insel, 2004). Functional consequences
of this subcellular localization have been assumed, as in
response to activation protein relocalization toward or
away from lipid rafts has been observed, and a variety of
signaling events is abolished if lipid rafts are disrupted.
Also, in nociception, lipid rafts are important. In behavioral
experiments, interferencewith fibronectin-integrin binding
attenuated PKC3-mediated hyperalgesia. In contrast,
PKA-mediated sensitization can be abolished by interfer-
ence with laminin-integrin binding (Dina et al., 2005). While
the latter effect is dependent on the integrity of lipid rafts,
the former is not. And indeed, reflecting these in vivo ob-
servations, biochemically only the laminin-binding integrin
a1 is found to be localized to lipid rafts in DRG neurons,
while the fibronectin-binding a5 integrin is not (Dina
et al., 2005). Other receptors involved in nociception
such as the b2-adrenergic receptor, the bradykinin recep-
tor 2 (deWeerd and Leeb-Lundberg, 1997), and the neuro-
kinin receptor 1 (Monastyrskaya et al., 2005) have been
found to be localized to membrane subdomains in non-
neuronal cells. Whether they compartmentalize to lipid
rafts also in nociceptive neurons and whether localization
of these receptors is relevant to nociceptor function
awaits further investigation.
The ‘‘Primed State’’: A New Mode of Sensitization
Two functional modes have been well described in noci-
ceptors: the naive or normal mode and the sensitized or
hyperalgesic mode. Recent work on PKC-dependent hy-
peralgesia suggests that there is an additional complexity
to consider, a mode referred to as the ‘‘primed state’’ (Fig-
ure 3; Aley et al., 2000). In the primed state, basal nocicep-
tive thresholds are still normal (Parada et al., 2003a). In-
stead of being sensitized against physical stimuli, the
nerve is sensitized against exposure to sensitizing agents.
In this primed state, far lower concentrations of inflamma-
tory mediators are sufficient to elicit enhanced and nota-
blymuch prolonged hyperalgesia. In contrast to traditional
sensitization induced by inflammatory mediators, whichrecovers within minutes to hours, neurons can remain in
the primed state for several weeks. Both the establish-
ment, which does not require prior hyperalgesia, and
maintenance of the primed state is PKC3 dependent
(Aley et al., 2000; Parada et al., 2003b). Inhibition or down-
regulation of PKC3 in rats five days after the establishment
of the primed state results in return to the initial nonprimed
state (Parada et al., 2003b). Given the long-lasting effects
of priming, this state could potentially underlie the chron-
ification of pain. Consistent with this idea, PKC3 also plays
a central role in models of chronic pain (Dina et al., 2000,
2001b; Joseph and Levine, 2003a, 2003b).
Plasticity of Signaling Cascades
Investigating the primed state not only shows the plasticity
of nociceptive neurons beyond the naive/sensitized di-
chotomy (see above) but also exemplifies the plasticity
in signaling pathways in response to the same stimulus.
PGE2-induced hyperalgesia in naive animals is mediated
by PKA. However, switching the nociceptive neuron
from the naive to the primed state leads to a shift in the un-
derlying signaling cascade. In the primed nociceptor,
PGE2 hyperalgesia is additionally mediated by PKC3
(Aley et al., 2000). While the mechanism underlying the
switch is unknown, the site of this switch nevertheless
has been narrowed down to a site downstream of adenylyl
cyclase activity but upstream of PKA activation (Parada
et al., 2005). This is surprising, as cAMP signaling is often
considered to be synonymous with PKA activity. Obvi-
ously, one component of a cascade should not be taken
to indicate involvement of the whole cascade, even if the
components can directly interact with each as do cAMP
and PKA. While switches of signaling pathways have
been described in other cellular systems (e.g., the switch
Figure 3. Three Modes of Sensitivity
Three neuronal states can be differentiated in the nociceptive neuron,
the naive, the just recently identified primed, and the hyperalgesic
state. (A) Exposure of the naive neuron to noxious physical or inflam-
matory stimuli (bold capital S) results in hyperalgesia (red area, B)
i.e., sensitization of the nerve toward future physical stimuli. Depen-
dent on the animal model the hyperalgesic state lasts for some few
hours. While the sensitivity to physical stimuli then returns to normal,
the sensitivity to successive inflammatory stimuli (small s, E) remains
increased. The primary afferent nociceptor remains in the primed state
(C). This state can be established also by treatment with small concen-
trations of inflammatory mediators (small s), which do not result in hy-
peralgesia (D, dotted line). In contrast to the hyperalgesic state, the
primed state is still present weeks later. The hyperalgesia induced in
the primed state is markedly prolonged (F). The establishment as
well as the maintenance of the primed state is PKC3-dependent. If in
the primed neuron PKC3 is blocked (G) the neuron returns to the naive
state (H).Neuron 55, August 2, 2007 ª2007 Elsevier Inc. 369
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role in nociceptive signaling remain largely unexplored.
Network of Signaling Pathways
Do the various pathways underlying nociception influence
each other, and if so, to what extent? In cultured DRGneu-
rons the induction of TTX-R INa-mediated sensitization by
PGE2 suggests PKC is a downstream effector of PKA
(Gold et al., 1998). Nevertheless, in vivo this relationship
is not observed (Taiwo and Levine, 1991). Similarly, an in-
terrelationship between the downstream components of
the b2-adrenergic receptor (i.e., PKA, PKC3, and ERK1/
2) is not transparent; each on its own induces robust me-
chanical hyperalgesia (Khasar et al., 1999a, 1999b). But
it remains unclear whether these pathways normally func-
tion in concert or whether they independently can result in
the same behavioral output. In both behavioral and bio-
chemical experiments, ERK1/2 appears not to depend
on either PKA or PKC (Aley et al., 2001), and PKC3 does
not depend on PKA (Hucho et al., 2005). However, po-
tential convergence further downstream has still to be
examined.
An additional aspect of the relationship of different sig-
naling pathways has to be investigated. Alessandri-Haber
et al. (2006) recently found a strong dependence for me-
chanical hyperalgesia on TRPV4 requiring both PKC3 as
well as PKA activation. This result suggests that the utiliza-
tion of combinations of signaling cascades can result in
changes in effector molecule modulation.
Cytoskeleton
Identification of the mechanism underlying crossactiva-
tion of PKC by cAMP adds a new class of proteins to no-
ciceptive signaling, Epac, a small family of GDP/GTP ex-
change factors acting on small G proteins (Hucho et al.,
2005). Small G proteins are involved in regulation of cyto-
skeletal elements. While a direct link between Epac and
the cytoskeleton in nociceptor signaling has not been es-
tablished, long-time drug treatment inducing stabilization
as well as destabilization ofmicrotubules produces painful
neuropathies in patients and neuropathic pain like behav-
ior in animals (Aley et al., 1996; Dina et al., 2001b). In con-
trast, short-term destruction of cytoskeletal components
dramatically attenuates the establishment of mechanical
hyperalgesia (Dina et al., 2003). Interestingly, interference
with sensitization was only observed for the PKC3-
mediated epinephrine-induced hyperalgesia but not for
PKA-dependent PGE2-induced hyperalgesia. But if PGE2-
induced sensitization is shifted from PKA to PKC3 depen-
dence by priming, then PGE2-induced hyperalgesia also
becomes dependent on cytoskeletal elements. In vitro de-
struction of microtubules also abrogated the epinephrine-
induced increase of TTX-R INa (Dina et al., 2003). Of note,
PKC3 has been described to bind to and potentially be ac-
tivated by the cytoskeleton (Prekeris et al., 1998). Indeed,
a link between the cytoskeleton and nociceptive signaling
components has been found also by a purely biochemical
approach. The C terminus of TRPV1 binds to tubulin and
thereby stabilizes microtubules specifically (Goswami
et al., 2004). Activation of TRPV1, in contrast, resulted in370 Neuron 55, August 2, 2007 ª2007 Elsevier Inc.rapid disassembly of microtubules leaving the neurofila-
ments and the actin cytoskeleton intact (Goswami et al.,
2006, 2007). The molecular mechanism of tubulin depen-
dent regulation of TRP channels still has to be unraveled.
Combined, these data suggest a critical role for the cy-
toskeletal matrix in nociceptor signaling. Given the limited
number of studies examining cytoskeletal interactions, it is
clear that additional research in this area is needed before
we can fully appreciate the impact that this structure has
on pain propagation.
The Extracellular Matrix
Extracellular as well as intracellular scaffolding proteins
are involved in the modulation of nociception. Changing
the interaction of the extracellular matrix with cell surface
integrin receptors completely inhibits the establishment of
mechanical hyperalgesia (Dina et al., 2004). Interestingly,
this effect shows differential specificity depending on the
intracellular signaling molecules involved. Interference
with the binding of the nociceptive neuron to laminin abol-
ishes PKA-mediated hyperalgesia. Conversely, blockade
of fibronectin receptors by various mechanisms specifi-
cally attenuates PKC3-dependent hyperalgesia.
Other extracellular matrix proteins may also have a role
in nociception. Markers such as TrkA or CGRP versus Ret
and Isolectin B4 (IB4) binding differentiate nociceptor sub-
populations. Recently, the protein carrying the epitope for
IB4 binding has been identified to be the extracellular ma-
trix proteoglycan versican (Bogen et al., 2005). About 70%
of the sensory neurons innervating the epidermis are pos-
itive for IB4. As the activation of PKC3 through as, adenylyl
cyclase, cAMP, Epac, and PLD/PLC was found to be spe-
cific for this subpopulation of nociceptive neurons (Hucho
et al., 2005), it will be of interest to test if versican or other
extracellular matrix molecules modulates the function of
the adjacent neurons.
Organelles
Important cellular functions, such as regulation of intracel-
lular Ca2+, aerobic energymetabolism, generation of reac-
tive oxygen species, and apoptosis are highly dependent
on mitochondria (Wei and Lee, 2002). Given their critical
role in cellular homeostasis and their high concentration
in the peripheral terminals of sensory neurons (Heppel-
mann et al., 1994), it is perhaps not surprising that
mitochondria were recently proposed to contribute to
nociceptor function (Joseph and Levine, 2004). Indeed, in-
terference with any of the five electron transport chain
complexes of themitochondrion resulted in marked atten-
uation of the mechanical hyperalgesia in models of AIDS
therapy, cancer therapy, and diabetic neuropathy (Joseph
and Levine, 2006). Interestingly, AIDS therapy-induced,
mitochondria function-dependent hyperalgesia appears
to be independent of PKA, PKC, ERK1/2, and NO. Con-
versely, hyperalgesia induced by epinephrine and PGE2
is not affected by inhibitors of the electron transport chain
(Joseph and Levine, 2006). Electron transport chain de-
pendence was also found for sphingomyelinase-depen-
dent and ceramide-induced hyperalgesia, downstream
mediators of TNFa and NGF in the induction of
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2002b). A signaling cascade including caspases appeared
tobe involved (JosephandLevine, 2004).Others have sug-
gested a role for mitochondria-derived reactive oxygen
species (Kim et al., 2004) and mitochondrial-regulated in-
tracellular calcium concentration (Kostyuk et al., 1999;
Shishkin et al., 2002) in nociceptor function. While details
have to be worked out, these data indicate the need to in-
vestigate nociceptive signaling in the context of normal cell
function and the neurons attempt to maintain homeostatic
balance.
Sex Hormones
Another emerging and still ill defined layer of regulation is
the actions of sex hormones. Both estrogen and androgen
receptors are present in DRG neurons (Patrone et al.,
1999). Indeed, sex-dependent differences in pain and
analgesia, both in humans and in animal models, are well
established (Berkley, 1997; Coyle et al., 1996; Dina et al.,
2001a; Gear et al., 1996). This sexual dimorphism includes
differences in pain as well as involvement of different
signaling pathways mediating sensitization of the primary
afferent nociceptor. In behavioral experiments, systemic
estrogen has been found to play a crucial role in the estab-
lishment of sex differences (Aloisi et al., 2002; Dina et al.,
2001a; Joseph et al., 2003). One aspect that has been in-
vestigated in greater detail is the role of the b2-adrenergic
receptor. In male rats, activation of the b2-adrenergic
receptor induces PKC3- as well as PKA- and ERK1/2-
dependentmechanical hyperalgesia. In contrast, in female
rats, b2-adrenergic receptor-mediated sensitization does
not require PKC3 (Dina et al., 2001a). This phenotype is
dependent on systemic estrogen levels. A similar depen-
dency was found on the cellular level, establishing that es-
trogen can act on the nociceptive neuron directly (Hucho
et al., 2006). Surprisingly, in cultured DRG neurons, the
action of estrogen is very fast. One minute preincubation
with estrogen abolishes the translocation of PKC3 in cul-
tured, male-derived sensory neurons, suggesting that
a transcription-independent mechanism is involved.
Fast actions of sex hormones have been shown also in
other systems (Falkenstein et al., 2000). A physiological
role for such fast concentration changes might exist in
pain pathways. The estrogen-producing enzyme aroma-
tase is present in the spinal dorsal horn, at sites where
peripheral nociceptive neurons terminate (Evrard and
Balthazart, 2003). Aromatase activity was recently found
to be involved in the establishment of thermal nociceptive
threshold (Evrard and Balthazart, 2003). Having the estro-
gen-producing enzyme and the estrogen receptors adja-
cent to each other opens the possibility that concentration
changes occur rapidly and only on a very local level, which
therefore might not be reflected in changes of the more
constant plasma levels. Indeed, a local rise in estrogen
by injection into the hindpaw results in complete abolition
of mechanical hyperalgesia (Hucho et al., 2006). Thus,
hormones could potentially have fast and local regulatory
functions beyond their classical organism-wide actions on
gene transcription.Nociceptive Signaling Is Context Dependent
As evident from the above, nociceptive signaling is depen-
dent on and can be modulated by a multitude of intracel-
lular second messenger pathways, ancillary proteins, and
organelles. Obviously, signaling is first of all dependent on
the presence of all components of the respective path-
way. But despite the presence of the initiating receptor
in all DRG neurons, PKC3 translocates only in IB4-positive
neurons (Hucho et al., 2005). Similarly, the NaV1.8 sodium
channel behaves differently in the context of IB4-positive
versus IB4-negative sensory neurons, both of which ex-
press this channel endogenously (Choi et al., 2007).
What defines the mechanistic specificity of this subgroup
of nociceptive neurons remains to be defined. Acknowl-
edging the apparent importance of the cellular context,
studies in cell lines have to be viewed with care (Vellani
et al., 2001). For example, when comparing different cell
lines transiently expressing TRPV1, phorbol ester-induced
sensitization of TRPV1 did not occur in cells with low en-
dogenous PKC3 concentration but could be ‘‘rescued’’
by the overexpression of PKC3 (Mandadi et al., 2006). Fur-
thermore, even if the same inducer seemingly activates
the same signaling cascade in vitro as in vivo, the receptor
subtypes involved can differ significantly (e.g., bradykinin
receptor 1 versus 2 and P2Y2 versus P2Y1; Moriyama
et al., 2003; Sugiura et al., 2002; Tominaga et al., 2001;
Vellani et al., 2004). It therefore is essential that, for the
pain field in particular, data derived from expression sys-
tems must be confirmed by experiments in animals and
primary cells.
Apart from differential involvement of signaling compo-
nents, the importance of temporal context is also critical.
For example, activation of PKC3 leads to mechanical
hyperalgesia (Hucho et al., 2005; Khasar et al., 1999a).
Surprisingly, if two hyperalgesia-inducing stimuli are ap-
plied consecutively, only the first establishes sensitization,
while the second aborts it, bringing the nociceptive
threshold back to baseline (Hucho et al., 2006). Apparently
as in other plastic neuronal systems, stimulus context
must be taken into account.
Nociceptor Cell Biology
Historically, research on peripheral and especially sensory
neurons led to the establishment of essential concepts in
neurobiology such as the understanding of sensors of
physical stimuli (e.g., rhodoposin), identification of nerve
growth factors and their receptors, the concept of target-
derived neurotrophins, neuronal differentiation through
a process of consecutive growth factor dependence,
andmany others. Further investigation of the fully differen-
tiated, very specialized, and highly plastic primary afferent
nociceptor still bears the potential not only to provide
a better understanding of nociceptive but also of neuronal
mechanisms in general. For example, work on these neu-
rons recently led to the realization that cAMP and PKC,
critical for neuronal plasticity and so far considered to act
in parallel, are in fact interconnected (Aley et al., 2000;
Hucho et al., 2005; Parada et al., 2005). Additionally, the
enormous recent excitement surrounding TRP channels,Neuron 55, August 2, 2007 ª2007 Elsevier Inc. 371
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ReviewFigure 4. A Cell-Biological Perspective
on Nociceptive Signaling
The primed state can develop and be main-
tained without overt hyperalgesia. Thus, sensi-
tization goes potentially beyond the acute
modification of ion channels, which define the
electrophysiological properties of nociceptors.
The cell-biological perspective led to the reali-
zation that organelles and cytoskeleton, aswell
as subcellular compartmentalization, are im-
portant components underlying sensitization.
It also helped focus on the influence of the sur-
rounding environment such as hormones, the
extracellular matrix, and neighboring cells.
Thereby, new pathways that produce hyperal-
gesia (black arrow-headed lines) and more im-
portantly of four new endogenous inhibitory
mechanisms (black blunt-ended lines) could
be identified. These pathways show specificity
for interference with PKA versus PKC3-depen-
dent hyperalgesic signaling. Thus, the interfer-
ence occurs upstream of the hypothetical noci-
ceptive module (large arrow, dark red area). To
what extent intracellular nociceptive signaling
occurs at the nerve terminus in the periphery,
along the nerve, in the cell body, or in the spinal
cord mostly remains to be defined.which was sparked by research on sensory neurons, has
now begun to extend to other tissues and cells, where
these molecules are also found to be expressed.
A surprisingly large number of important conceptual
questions still remain to be solved. Given the function of
nociceptive neurons in acute tissue protection, why are
they the slowest conducting cells in the somatosensory
system? Why, given the poor spatial localization of pain,
are there so many nociceptors in peripheral tissues?
Why, in contrast to all other sensory systems, is the sensa-
tion still ongoing and sometimes increasing when a con-
stant stimulus is applied and even after the stimulus is
gone? And how is long-lasting potentiation as the result
of complex associative stimuli accomplished in a neuronal
system without classical input stimuli and without clas-
sical input structures such as neurotransmitters and
synapses?
By asking for clarification of the subcellular organization
and thus the exact molecular mechanisms of nociception,
the emerging cell-biological picture of nociceptor function
may provide us with a fresh perspective and new avenues
for research (Figure 4). Most of the known extracellular
sensitizers are inflammatory mediators. As noxious stimuli
are potentially tissue damaging, resulting in inflammation,
could the nociceptor be first of all a surveillance tool of tis-
sue integrity? As proof of principal supporting this notion,
the importance of integrin-extracellular matrix interaction
has been shown.What other cell-cell and cell-matrix com-
ponent interactions might play a role? Is there, as in other
systems, not only outside-in but also inside-out signaling?
Furthermore, the cytoskeleton, themitochondrion, and the
submembrane organization of signaling components in
signaling hot spots (e.g., lipid rafts) have been shown to
play a role in nociception. What other organelles, intracel-372 Neuron 55, August 2, 2007 ª2007 Elsevier Inc.lular subcompartments, and second messengers are
involved and in which cellular context? And, last but not
least, will it be possible to define more mechanism-based
phenotypes, if signaling occurs in parallel, or can one
characterize a nociceptivemodule if convergence occurs?
For addressing these questions, methodological ap-
proaches must evolve. Such evolution is in progress. For
example, sensory neurons, notoriously resistant against
transfection, can now be molecularly altered through
new electroporation methods as well as viral techniques.
The broad surveillance of transcriptional changes in small
subsets or even single cells is also increasingly feasible, as
are imaging techniques enabling visualization of signaling
activity. And, not last, genetic analysis of pain phenotypes
inmodel organisms as well as in humanswill provide a rich
field of data that should help to complement the classical
pharmacological approaches in pain research.
Still 100 years after Santiago Ramo´n y Cajal won the
Nobel Prize for his pioneering work on sensory neurons,
among others, these cells still harbor many important
mysteries and potential answers about fundamental ques-
tions in cellular neurobiology. Pain research bears the bur-
den tobridgemolecular andcellular events, and acomplex
phenotype. In this way it is hoped that the combined ef-
forts from different areas of neuroscience will ultimately
result in overcoming current therapeutic stumbling blocks,
helping to address a major unmet medical need.
ACKNOWLEDGMENTS
Many thanks to Professors Michael Gold and Ferdinand Hucho for crit-
ically reading versions of this manuscript and making constructive
comments. Apologies for not being able, due to space constraints,
to more fully reference all investigators who have contributed to the
field.
Neuron
ReviewREFERENCES
Alessandri-Haber, N., Dina, O.A., Joseph, E.K., Reichling, D., and Lev-
ine, J.D. (2006). A transient receptor potential vanilloid 4-dependent
mechanism of hyperalgesia is engaged by concerted action of inflam-
matory mediators. J. Neurosci. 26, 3864–3874.
Aley, K.O., and Levine, J.D. (1997). Dissociation of tolerance and de-
pendence for opioid peripheral antinociception in rats. J. Neurosci.
17, 3907–3912.
Aley, K.O., and Levine, J.D. (1999). Role of protein kinase A in themain-
tenance of inflammatory pain. J. Neurosci. 19, 2181–2186.
Aley, K.O., Reichling, D.B., and Levine, J.D. (1996). Vincristine hyper-
algesia in the rat: a model of painful vincristine neuropathy in humans.
Neuroscience 73, 259–265.
Aley, K.O., McCarter, G., and Levine, J.D. (1998). Nitric oxide signaling
in pain and nociceptor sensitization in the rat. J. Neurosci. 18, 7008–
7014.
Aley, K.O., Messing, R.O., Mochly-Rosen, D., and Levine, J.D. (2000).
Chronic hypersensitivity for inflammatory nociceptor sensitization me-
diated by the epsilon isozyme of protein kinase C. J. Neurosci. 20,
4680–4685.
Aley, K.O., Martin, A., McMahon, T., Mok, J., Levine, J.D., and
Messing, R.O. (2001). Nociceptor sensitization by extracellular signal-
regulated kinases. J. Neurosci. 21, 6933–6939.
Aloisi, A.M., Della Seta, D., Rendo, C., Ceccarelli, I., Scaramuzzino, A.,
and Farabollini, F. (2002). Exposure to the estrogenic pollutant bisphe-
nol A affects pain behavior induced by subcutaneous formalin injection
in male and female rats. Brain Res. 937, 1–7.
Amadesi, S., Cottrell, G.S., Divino, L., Chapman, K., Grady, E.F.,
Bautista, F., Karanjia, R., Barajas-Lopez, C., Vanner, S., Vergnolle,
N., and Bunnett, N.W. (2006). Protease-activated receptor 2 sensitizes
TRPV1 by protein kinase Cepsilon- and A-dependent mechanisms in
rats and mice. J. Physiol. 575, 555–571.
Averill, S., Delcroix, J.D., Michael, G.J., Tomlinson, D.R., Fernyhough,
P., and Priestley, J.V. (2001). Nerve growth factor modulates the acti-
vation status and fast axonal transport of ERK 1/2 in adult nociceptive
neurones. Mol. Cell. Neurosci. 18, 183–196.
Berkley, K.J. (1997). Sex differences in pain. Behav. Brain Sci. 20, 371–
380.
Bhave, G., Zhu, W., Wang, H., Brasier, D.J., Oxford, G.S., and Gereau,
R.W. (2002). cAMP-dependent protein kinase regulates desensitiza-
tion of the capsaicin receptor (VR1) by direct phosphorylation. Neuron
35, 721–731.
Bhave, G., Hu, H.J., Glauner, K.S., Zhu, W., Wang, H., Brasier, D.J.,
Oxford, G.S., and Gereau, R.W. (2003). Protein kinase C phosphoryla-
tion sensitizes but does not activate the capsaicin receptor transient
receptor potential vanilloid 1 (TRPV1). Proc. Natl. Acad. Sci. USA
100, 12480–12485.
Bogen, O., Dreger, M., Gillen, C., Schroder, W., and Hucho, F. (2005).
Identification of versican as an isolectin B4-binding glycoprotein from
mammalian spinal cord tissue. FEBS J. 272, 1090–1102.
Burgess, G.M., Mullaney, I., McNeill, M., Coote, P.R., Minhas, A., and
Wood, J.N. (1989a). Activation of guanylate cyclase by bradykinin in rat
sensory neurones is mediated by calcium influx: possible role of the in-
crease in cyclic GMP. J. Neurochem. 53, 1212–1218.
Burgess, G.M., Mullaney, I., McNeill, M., Dunn, P.M., and Rang, H.P.
(1989b). Second messengers involved in the mechanism of action of
bradykinin in sensory neurons in culture. J. Neurosci. 9, 3314–3325.
Cesare, P., andMcNaughton, P. (1996). A novel heat-activated current
in nociceptive neurons and its sensitization by bradykinin. Proc. Natl.
Acad. Sci. USA 93, 15435–15439.
Cesare, P., Dekker, L.V., Sardini, A., Parker, P.J., and McNaughton,
P.A. (1999). Specific involvement of PKC-epsilon in sensitization of
the neuronal response to painful heat. Neuron 23, 617–624.Chen, X., and Levine, J.D. (1999). NOS inhibitor antagonism of PGE2-
induced mechanical sensitization of cutaneous C-fiber nociceptors in
the rat. J. Neurophysiol. 81, 963–966.
Choi, Y., Raja, S.N., Moore, L.C., and Tobin, J.R. (1996). Neuropathic
pain in rats is associated with altered nitric oxide synthase activity in
neural tissue. J. Neurol. Sci. 138, 14–20.
Choi, J.S., Dib-Hajj, S.D., and Waxman, S.G. (2007). Differential slow
inactivation and use-dependent inhibition of Nav1.8 channels contrib-
ute to distinct firing properties in IB4+ and IB4 DRG neurons. J. Neu-
rophysiol. 97, 1258–1265.
Collier, H.O., and Roy, A.C. (1974). Morphine-like drugs inhibit the
stimulation of E prostaglandins of cyclic AMP formation by rat brain
homogenate. Nature 248, 24–27.
Coyle, D.E., Sehlhorst, C.S., and Behbehani, M.M. (1996). Intact fe-
male rats are more susceptible to the development of tactile allodynia
than ovariectomized female rats following partial sciatic nerve ligation
(PSNL). Neurosci. Lett. 203, 37–40.
Crandall, M., Kwash, J., Yu, W., and White, G. (2002). Activation of
protein kinase C sensitizes human VR1 to capsaicin and to moderate
decreases in pH at physiological temperatures in Xenopus oocytes.
Pain 98, 109–117.
Cui, M., andNicol, G.D. (1995). Cyclic AMPmediates the prostaglandin
E2-induced potentiation of bradykinin excitation in rat sensory neu-
rons. Neuroscience 66, 459–466.
Dai, Y., Iwata, K., Fukuoka, T., Kondo, E., Tokunaga, A., Yamanaka, H.,
Tachibana, T., Liu, Y., and Noguchi, K. (2002). Phosphorylation of
extracellular signal-regulated kinase in primary afferent neurons by
noxious stimuli and its involvement in peripheral sensitization.
J. Neurosci. 22, 7737–7745.
de Rooij, J., Zwartkruis, F.J., Verheijen, M.H., Cool, R.H., Nijman, S.M.,
Wittinghofer, A., and Bos, J.L. (1998). Epac is a Rap1 guanine-
nucleotide-exchange factor directly activated by cyclic AMP. Nature
396, 474–477.
de Weerd, W.F., and Leeb-Lundberg, L.M. (1997). Bradykinin seques-
ters B2 bradykinin receptors and the receptor-coupled Galpha sub-
units Galphaq and Galphai in caveolae in DDT1 MF-2 smooth muscle
cells. J. Biol. Chem. 272, 17858–17866.
Delcroix, J.D., Valletta, J.S., Wu, C., Hunt, S.J., Kowal, A.S., and
Mobley, W.C. (2003). NGF signaling in sensory neurons: evidence
that early endosomes carry NGF retrograde signals. Neuron 39, 69–84.
Dina, O.A., Barletta, J., Chen, X., Mutero, A., Martin, A., Messing, R.O.,
and Levine, J.D. (2000). Key role for the epsilon isoform of protein ki-
nase C in painful alcoholic neuropathy in the rat. J. Neurosci. 20,
8614–8619.
Dina, O.A., Aley, K.O., Isenberg, W., Messing, R.O., and Levine, J.D.
(2001a). Sex hormones regulate the contribution of PKCepsilon and
PKA signalling in inflammatory pain in the rat. Eur. J. Neurosci. 13,
2227–2233.
Dina, O.A., Chen, X., Reichling, D., and Levine, J.D. (2001b). Role of
protein kinase Cepsilon and protein kinase A in a model of pacli-
taxel-induced painful peripheral neuropathy in the rat. Neuroscience
108, 507–515.
Dina, O.A., McCarter, G.C., de Coupade, C., and Levine, J.D. (2003).
Role of the sensory neuron cytoskeleton in second messenger signal-
ing for inflammatory pain. Neuron 39, 613–624.
Dina, O.A., Parada, C.A., Yeh, J., Chen, X., McCarter, G.C., and Lev-
ine, J.D. (2004). Integrin signaling in inflammatory and neuropathic
pain in the rat. Eur. J. Neurosci. 19, 634–642.
Dina, O.A., Hucho, T., Yeh, J., Malik-Hall, M., Reichling, D.B., and Lev-
ine, J.D. (2005). Primary afferent second messenger cascades interact
with specific integrin subunits in producing inflammatory hyperalgesia.
Pain 115, 191–203.Neuron 55, August 2, 2007 ª2007 Elsevier Inc. 373
Neuron
ReviewDray, A., Bettaney, J., Forster, P., and Perkins, M.N. (1988). Bradyki-
nin-induced stimulation of afferent fibres is mediated through protein
kinase C. Neurosci. Lett. 91, 301–307.
Duarte, I.D., dos Santos, I.R., Lorenzetti, B.B., and Ferreira, S.H.
(1992). Analgesia by direct antagonism of nociceptor sensitization in-
volves the arginine-nitric oxide-cGMP pathway. Eur. J. Pharmacol.
217, 225–227.
England, S., Bevan, S., and Docherty, R.J. (1996). PGE2modulates the
tetrodotoxin-resistant sodium current in neonatal rat dorsal root gan-
glion neurones via the cyclic AMP-protein kinase A cascade. J. Phys-
iol. 495, 429–440.
Evrard, H.C., and Balthazart, J. (2003). Aromatase (estrogen synthase)
activity in the dorsal horn of the spinal cord: functional implications.
Ann. N Y Acad. Sci. 1007, 263–271.
Falkenstein, E., Tillmann, H.C., Christ, M., Feuring,M., andWehling, M.
(2000). Multiple actions of steroid hormones—a focus on rapid, nonge-
nomic effects. Pharmacol. Rev. 52, 513–556.
Ferreira, S.H., and Nakamura, M. (1979). II - Prostaglandin hyperalge-
sia: the peripheral analgesic activity of morphine, enkephalins and opi-
oid antagonists. Prostaglandins 18, 191–200.
Ferreira, S.H., Lorenzetti, B.B., and De Campos, D.I. (1990). Induction,
blockade and restoration of a persistent hypersensitive state. Pain 42,
365–371.
Fitzgerald, E.M., Okuse, K., Wood, J.N., Dolphin, A.C., and Moss, S.J.
(1999). cAMP-dependent phosphorylation of the tetrodotoxin-resis-
tant voltage-dependent sodium channel SNS. J. Physiol. 516, 433–
446.
Freeman, M. (1996). Reiterative use of the EGF receptor triggers differ-
entiation of all cell types in the Drosophila eye. Cell 87, 651–660.
Gear, R.W.,Miaskowski, C., Gordon, N.C., Paul, S.M., Heller, P.H., and
Levine, J.D. (1996). Kappa-opioids produce significantly greater anal-
gesia in women than in men. Nat. Med. 2, 1248–1250.
Gold, M.S., Reichling, D.B., Shuster, M.J., and Levine, J.D. (1996).
Hyperalgesic agents increase a tetrodotoxin-resistant Na+ current in
nociceptors. Proc. Natl. Acad. Sci. USA 93, 1108–1112.
Gold, M.S., Levine, J.D., and Correa, A.M. (1998). Modulation of TTX-R
INa by PKC and PKA and their role in PGE2-induced sensitization of rat
sensory neurons in vitro. J. Neurosci. 18, 10345–10355.
Goswami, C., Dreger, M., Jahnel, R., Bogen, O., Gillen, C., and Hucho,
F. (2004). Identification and characterization of a Ca2+-sensitive inter-
action of the vanilloid receptor TRPV1 with tubulin. J. Neurochem. 91,
1092–1103.
Goswami, C., Dreger, M., Otto, H., Schwappach, B., and Hucho, F.
(2006). Rapid disassembly of dynamic microtubules upon activation
of the capsaicin receptor TRPV1. J. Neurochem. 96, 254–266.
Goswami, C., Schmidt, H., and Hucho, F. (2007). TRPV1 at nerve end-
ings regulates growth cone morphology and movement through cyto-
skeleton reorganization. FEBS J. 274, 760–772.
Heppelmann, B., Messlinger, K., Neiss, W.F., and Schmidt, R.F.
(1994). Mitochondria in fine afferent nerve fibres of the knee joint in
the cat: a quantitative electron-microscopical examination. Cell Tissue
Res. 275, 493–501.
Hingtgen, C.M., Waite, K.J., and Vasko, M.R. (1995). Prostaglandins
facilitate peptide release from rat sensory neurons by activating the
adenosine 30,50-cyclic monophosphate transduction cascade. J. Neu-
rosci. 15, 5411–5419.
Holthusen, H., and Arndt, J.O. (1994). Nitric oxide evokes pain in hu-
mans on intracutaneous injection. Neurosci. Lett. 165, 71–74.
Hucho, T.B., Dina, O.A., and Levine, J.D. (2005). Epac mediates
a cAMP-to-PKC signaling in inflammatory pain: an isolectin B4(+) neu-
ron-specific mechanism. J. Neurosci. 25, 6119–6126.374 Neuron 55, August 2, 2007 ª2007 Elsevier Inc.Hucho, T.B., Dina, O.A., Kuhn, J., and Levine, J.D. (2006). Estrogen
controls PKCepsilon-dependent mechanical hyperalgesia through di-
rect action on nociceptive neurons. Eur. J. Neurosci. 24, 527–534.
Ji, R.R., Baba, H., Brenner, G.J., and Woolf, C.J. (1999). Nociceptive-
specific activation of ERK in spinal neurons contributes to pain hyper-
sensitivity. Nat. Neurosci. 2, 1114–1119.
Ji, R.R., Samad, T.A., Jin, S.X., Schmoll, R., andWoolf, C.J. (2002). p38
MAPK activation by NGF in primary sensory neurons after inflamma-
tion increases TRPV1 levels and maintains heat hyperalgesia. Neuron
36, 57–68.
Jin, S.X., Zhuang, Z.Y., Woolf, C.J., and Ji, R.R. (2003). p38 mitogen-
activated protein kinase is activated after a spinal nerve ligation in spi-
nal cord microglia and dorsal root ganglion neurons and contributes to
the generation of neuropathic pain. J. Neurosci. 23, 4017–4022.
Jin, X., and Gereau, R.W. (2006). Acute p38-mediated modulation of
tetrodotoxin-resistant sodium channels in mouse sensory neurons
by tumor necrosis factor-alpha. J. Neurosci. 26, 246–255.
Joseph, E.K., and Levine, J.D. (2003a). Sexual dimorphism for protein
kinase c epsilon signaling in a rat model of vincristine-induced painful
peripheral neuropathy. Neuroscience 119, 831–838.
Joseph, E.K., and Levine, J.D. (2003b). Sexual dimorphism in the
contribution of protein kinase C isoforms to nociception in the strepto-
zotocin diabetic rat. Neuroscience 120, 907–913.
Joseph, E.K., and Levine, J.D. (2004). Caspase signalling in neuro-
pathic and inflammatory pain in the rat. Eur. J. Neurosci. 20, 2896–
2902.
Joseph, E.K., and Levine, J.D. (2006). Mitochondrial electron transport
in models of neuropathic and inflammatory pain. Pain 121, 105–114.
Joseph, E.K., Parada, C.A., and Levine, J.D. (2003). Hyperalgesic
priming in the rat demonstrates marked sexual dimorphism. Pain
105, 143–150.
Julius, D., and Basbaum, A.I. (2001). Molecular mechanisms of noci-
ception. Nature 413, 203–210.
Kaupp, U.B., and Seifert, R. (2002). Cyclic nucleotide-gated ion chan-
nels. Physiol. Rev. 82, 769–824.
Kawabata, A., Manabe, S., Manabe, Y., and Takagi, H. (1994). Effect of
topical administration of L-arginine on formalin-induced nociception in
the mouse: a dual role of peripherally formed NO in pain modulation.
Br. J. Pharmacol. 112, 547–550.
Kawasaki, H., Springett, G.M., Mochizuki, N., Toki, S., Nakaya, M.,
Matsuda, M., Housman, D.E., and Graybiel, A.M. (1998). A family of
cAMP-binding proteins that directly activate Rap1. Science 282,
2275–2279.
Kenney, A.M., and Kocsis, J.D. (1998). Peripheral axotomy induces
long-term c-Jun amino-terminal kinase-1 activation and activator pro-
tein-1 binding activity by c-Jun and junD in adult rat dorsal root ganglia
In vivo. J. Neurosci. 18, 1318–1328.
Kessler, F., Habelt, C., Averbeck, B., Reeh, P.W., and Kress, M. (1999).
Heat-induced release of CGRP from isolated rat skin and effects of
bradykinin and the protein kinase C activator PMA. Pain 83, 289–295.
Khasar, S.G., Lin, Y.H., Martin, A., Dadgar, J., McMahon, T., Wang, D.,
Hundle, B., Aley, K.O., Isenberg, W., McCarter, G., et al. (1999a). A
novel nociceptor signaling pathway revealed in protein kinase C epsi-
lon mutant mice. Neuron 24, 253–260.
Khasar, S.G., McCarter, G., and Levine, J.D. (1999b). Epinephrine pro-
duces a beta-adrenergic receptor-mediated mechanical hyperalgesia
and in vitro sensitization of rat nociceptors. J. Neurophysiol. 81, 1104–
1112.
Kim, S.Y., Bae, J.C., Kim, J.Y., Lee, H.L., Lee, K.M., Kim, D.S., and
Cho, H.J. (2002). Activation of p38 MAP kinase in the rat dorsal root
ganglia and spinal cord following peripheral inflammation and nerve in-
jury. Neuroreport 13, 2483–2486.
Neuron
ReviewKim, H.K., Park, S.K., Zhou, J.L., Taglialatela, G., Chung, K., Cogge-
shall, R.E., and Chung, J.M. (2004). Reactive oxygen species (ROS)
play an important role in a rat model of neuropathic pain. Pain 111,
116–124.
Kostyuk, E., Svichar, N., Shishkin, V., and Kostyuk, P. (1999). Role of
mitochondrial dysfunction in calcium signalling alterations in dorsal
root ganglion neurons of mice with experimentally-induced diabetes.
Neuroscience 90, 535–541.
Kress, M., Rodl, J., and Reeh, P.W. (1996). Stable analogues of cyclic
AMPbut not cyclic GMP sensitize unmyelinated primary afferents in rat
skin to heat stimulation but not to inflammatory mediators, in vitro.
Neuroscience 74, 609–617.
Lewin, M.R., and Walters, E.T. (1999). Cyclic GMP pathway is critical
for inducing long-term sensitization of nociceptive sensory neurons.
Nat. Neurosci. 2, 18–23.
Lewin, G.R., and Moshourab, R. (2004). Mechanosensation and pain.
J. Neurobiol. 61, 30–44.
Lewin, G.R., Lu, Y., and Park, T.J. (2004). A plethora of painful mole-
cules. Curr. Opin. Neurobiol. 14, 443–449.
Lopshire, J.C., and Nicol, G.D. (1998). The cAMP transduction cas-
cade mediates the prostaglandin E2 enhancement of the capsaicin-
elicited current in rat sensory neurons: whole-cell and single-channel
studies. J. Neurosci. 18, 6081–6092.
Majewski, M., Sienkiewicz, W., Kaleczyc, J., Mayer, B., Czaja, K., and
Lakomy, M. (1995). The distribution and co-localization of immunore-
activity to nitric oxide synthase, vasoactive intestinal polypeptide
and substance P within nerve fibres supplying bovine and porcine
female genital organs. Cell Tissue Res. 281, 445–464.
Malik-Hall, M., Dina, O.A., and Levine, J.D. (2005). Primary afferent no-
ciceptor mechanisms mediating NGF-induced mechanical hyperalge-
sia. Eur. J. Neurosci. 21, 3387–3394.
Malmberg, A.B., Brandon, E.P., Idzerda, R.L., Liu, H., McKnight, G.S.,
and Basbaum, A.I. (1997). Diminished inflammation and nociceptive
pain with preservation of neuropathic pain in mice with a targeted
mutation of the type I regulatory subunit of cAMP-dependent protein
kinase. J. Neurosci. 17, 7462–7470.
Mandadi, S., Tominaga, T., Numazaki, M., Murayama, N., Saito, N.,
Armati, P.J., Roufogalis, B.D., and Tominaga, M. (2006). Increased
sensitivity of desensitized TRPV1 by PMA occurs through PKCepsilon-
mediated phosphorylation at S800. Pain 123, 106–116.
Mizushima, T., Obata, K., Yamanaka, H., Dai, Y., Fukuoka, T., Toku-
naga, A., Mashimo, T., and Noguchi, K. (2005). Activation of p38
MAPK in primary afferent neurons by noxious stimulation and its
involvement in the development of thermal hyperalgesia. Pain 113,
51–60.
Monastyrskaya, K., Hostettler, A., Buergi, S., and Draeger, A. (2005).
The NK1 receptor localizes to the plasma membrane microdomains,
and its activation is dependent on lipid raft integrity. J. Biol. Chem.
280, 7135–7146.
Moore, P.K., Wallace, P., Gaffen, Z., Hart, S.L., and Babbedge, R.C.
(1993). Characterization of the novel nitric oxide synthase inhibitor
7-nitro indazole and related indazoles: antinociceptive and cardiovas-
cular effects. Br. J. Pharmacol. 110, 219–224.
Morenilla-Palao, C., Planells-Cases, R., Garcia-Sanz, N., and Ferrer-
Montiel, A. (2004). Regulated exocytosis contributes to protein kinase
C potentiation of vanilloid receptor activity. J. Biol. Chem. 279, 25665–
25672.
Moriyama, T., Iida, T., Kobayashi, K., Higashi, T., Fukuoka, T.,
Tsumura, H., Leon, C., Suzuki, N., Inoue, K., Gachet, C., et al.
(2003). Possible involvement of P2Y2 metabotropic receptors in
ATP-induced transient receptor potential vanilloid receptor 1-medi-
ated thermal hypersensitivity. J. Neurosci. 23, 6058–6062.
Nestler, E.J. (2004). Historical review: Molecular and cellular mecha-
nisms of opiate and cocaine addiction. Trends Pharmacol. Sci. 25,
210–218.Numazaki, M., Tominaga, T., Toyooka, H., and Tominaga, M. (2002).
Direct phosphorylation of capsaicin receptor VR1 by protein kinase
Cepsilon and identification of two target serine residues. J. Biol.
Chem. 277, 13375–13378.
Obata, K., Yamanaka, H., Dai, Y., Tachibana, T., Fukuoka, T., Toku-
naga, A., Yoshikawa, H., and Noguchi, K. (2003). Differential activation
of extracellular signal-regulated protein kinase in primary afferent neu-
rons regulates brain-derived neurotrophic factor expression after pe-
ripheral inflammation and nerve injury. J. Neurosci. 23, 4117–4126.
Olah, Z., Karai, L., and Iadarola, M.J. (2002). Protein kinase C(alpha) is
required for vanilloid receptor 1 activation. Evidence for multiple sig-
naling pathways. J. Biol. Chem. 277, 35752–35759.
Oshita, K., Inoue, A., Tang, H.B., Nakata, Y., Kawamoto, M., and Yuge,
O. (2005). CB(1) cannabinoid receptor stimulation modulates transient
receptor potential vanilloid receptor 1 activities in calcium influx and
substance P release in cultured rat dorsal root ganglion cells. J. Phar-
macol. Sci. 97, 377–385.
Ostrom, R.S., and Insel, P.A. (2004). The evolving role of lipid rafts and
caveolae in G protein-coupled receptor signaling: implications for mo-
lecular pharmacology. Br. J. Pharmacol. 143, 235–245.
Parada, C.A., Yeh, J.J., Joseph, E.K., and Levine, J.D. (2003a). Tumor
necrosis factor receptor type-1 in sensory neurons contributes to in-
duction of chronic enhancement of inflammatory hyperalgesia in rat.
Eur. J. Neurosci. 17, 1847–1852.
Parada, C.A., Yeh, J.J., Reichling, D.B., and Levine, J.D. (2003b). Tran-
sient attenuation of protein kinase Cepsilon can terminate a chronic
hyperalgesic state in the rat. Neuroscience 120, 219–226.
Parada, C.A., Reichling, D.B., and Levine, J.D. (2005). Chronic hyper-
algesic priming in the rat involves a novel interaction between cAMP
and PKCvarepsilon second messenger pathways. Pain 113, 185–190.
Patrone, C., Andersson, S., Korhonen, L., and Lindholm, D. (1999). Es-
trogen receptor-dependent regulation of sensory neuron survival in
developing dorsal root ganglion. Proc. Natl. Acad. Sci. USA 96,
10905–10910.
Pitchford, S., and Levine, J.D. (1991). Prostaglandins sensitize noci-
ceptors in cell culture. Neurosci. Lett. 132, 105–108.
Pollock, J., McFarlane, S.M., Connell, M.C., Zehavi, U., Vandenabeele,
P., MacEwan, D.J., and Scott, R.H. (2002). TNF-alpha receptors simul-
taneously activate Ca2+ mobilisation and stress kinases in cultured
sensory neurones. Neuropharmacology 42, 93–106.
Prekeris, R., Hernandez, R.M., Mayhew, M.W., White, M.K., and
Terrian, D.M. (1998). Molecular analysis of the interactions between
protein kinase C-epsilon and filamentous actin. J. Biol. Chem. 273,
26790–26798.
Premkumar, L.S., and Ahern, G.P. (2000). Induction of vanilloid recep-
tor channel activity by protein kinase C. Nature 408, 985–990.
Qian, Y., Chao, D.S., Santillano, D.R., Cornwell, T.L., Nairn, A.C.,
Greengard, P., Lincoln, T.M., and Bredt, D.S. (1996). cGMP-depen-
dent protein kinase in dorsal root ganglion: relationship with nitric
oxide synthase and nociceptive neurons. J. Neurosci. 16, 3130–3138.
Rang, H.P., and Ritchie, J.M. (1988). Depolarization of nonmyelinated
fibers of the rat vagus nerve produced by activation of protein kinase
C. J. Neurosci. 8, 2606–2617.
Schafers, M., Svensson, C.I., Sommer, C., and Sorkin, L.S. (2003). Tu-
mor necrosis factor-alpha induces mechanical allodynia after spinal
nerve ligation by activation of p38 MAPK in primary sensory neurons.
J. Neurosci. 23, 2517–2521.
Schepelmann, K., Messlinger, K., and Schmidt, R.F. (1993). The
effects of phorbol ester on slowly conducting afferents of the cat’s
knee joint. Exp. Brain Res. 92, 391–398.
Scholz, J., and Woolf, C.J. (2002). Can we conquer pain? Nat. Neuro-
sci. 5 (Suppl.), 1062–1067.Neuron 55, August 2, 2007 ª2007 Elsevier Inc. 375
Neuron
ReviewShishkin, V., Potapenko, E., Kostyuk, E., Girnyk, O., Voitenko, N., and
Kostyuk, P. (2002). Role of mitochondria in intracellular calcium signal-
ing in primary and secondary sensory neurones of rats. Cell Calcium
32, 121–130.
Souza, A.L., Moreira, F.A., Almeida, K.R., Bertollo, C.M., Costa, K.A.,
and Coelho, M.M. (2002). In vivo evidence for a role of protein kinase
C in peripheral nociceptive processing. Br. J. Pharmacol. 135, 239–
247.
Steel, J.H., Terenghi, G., Chung, J.M., Na, H.S., Carlton, S.M., and Po-
lak, J.M. (1994). Increased nitric oxide synthase immunoreactivity in rat
dorsal root ganglia in a neuropathic pain model. Neurosci. Lett. 169,
81–84.
Stein, C., Millan, M.J., Shippenberg, T.S., Peter, K., and Herz, A.
(1989). Peripheral opioid receptors mediating antinociception in in-
flammation. Evidence for involvement of mu, delta and kappa recep-
tors. J. Pharmacol. Exp. Ther. 248, 1269–1275.
Sugiura, T., Tominaga, M., Katsuya, H., and Mizumura, K. (2002). Bra-
dykinin lowers the threshold temperature for heat activation of vanilloid
receptor 1. J. Neurophysiol. 88, 544–548.
Taiwo, Y.O., and Levine, J.D. (1991). Further confirmation of the role of
adenyl cyclase and of cAMP-dependent protein kinase in primary af-
ferent hyperalgesia. Neuroscience 44, 131–135.
Taiwo, Y.O., Bjerknes, L.K., Goetzl, E.J., and Levine, J.D. (1989).
Mediation of primary afferent peripheral hyperalgesia by the cAMP
second messenger system. Neuroscience 32, 577–580.
Thomas, D.A., Ren, K., Besse, D., Ruda, M.A., and Dubner, R. (1996).
Application of nitric oxide synthase inhibitor, N omega-nitro-L-arginine
methyl ester, on injured nerve attenuates neuropathy-induced thermal
hyperalgesia in rats. Neurosci. Lett. 210, 124–126.
Tominaga, M., Wada, M., and Masu, M. (2001). Potentiation of capsa-
icin receptor activity by metabotropic ATP receptors as a possible
mechanism for ATP-evoked pain and hyperalgesia. Proc. Natl. Acad.
Sci. USA 98, 6951–6956.
Van Buren, J.J., Bhat, S., Rotello, R., Pauza, M.E., and Premkumar,
L.S. (2005). Sensitization and translocation of TRPV1 by insulin and
IGF-I. Mol. Pain 1, 17.376 Neuron 55, August 2, 2007 ª2007 Elsevier Inc.Vellani, V., Mapplebeck, S., Moriondo, A., Davis, J.B., and McNaugh-
ton, P.A. (2001). Protein kinase C activation potentiates gating of the
vanilloid receptor VR1 by capsaicin, protons, heat and anandamide.
J. Physiol. 534, 813–825.
Vellani, V., Zachrisson, O., and McNaughton, P.A. (2004). Functional
bradykinin B1 receptors are expressed in nociceptive neurons and
are upregulated by GDNF. J. Physiol. 560 (Pt. 2), 391–401.
Vivancos, G.G., Parada, C.A., and Ferreira, S.H. (2003). Opposite
nociceptive effects of the arginine/NO/cGMP pathway stimulation in
dermal and subcutaneous tissues. Br. J. Pharmacol. 138, 1351–1357.
Vizzard, M.A., Erdman, S.L., and de Groat, W.C. (1995). Increased ex-
pression of neuronal nitric oxide synthase in dorsal root ganglion neu-
rons after systemic capsaicin administration. Neuroscience 67, 1–5.
Vizzard, M.A., Erdman, S.L., and de Groat, W.C. (1996). Increased ex-
pression of neuronal nitric oxide synthase in bladder afferent pathways
following chronic bladder irritation. J. Comp. Neurol. 370, 191–202.
Wei, Y.H., and Lee, H.C. (2002). Oxidative stress, mitochondrial DNA
mutation, and impairment of antioxidant enzymes in aging. Exp. Biol.
Med. (Maywood) 227, 671–682.
Wiesenfeld-Hallin, Z., Hao, J.X., Xu, X.J., and Hokfelt, T. (1993). Nitric
oxide mediates ongoing discharges in dorsal root ganglion cells after
peripheral nerve injury. J. Neurophysiol. 70, 2350–2353.
Zhang, X., Verge, V., Wiesenfeld-Hallin, Z., Ju, G., Bredt, D., Synder,
S.H., and Hokfelt, T. (1993). Nitric oxide synthase-like immunoreactiv-
ity in lumbar dorsal root ganglia and spinal cord of rat and monkey and
effect of peripheral axotomy. J. Comp. Neurol. 335, 563–575.
Zhang, J.M., Li, H., Liu, B., and Brull, S.J. (2002a). Acute topical appli-
cation of tumor necrosis factor alpha evokes protein kinase A-depen-
dent responses in rat sensory neurons. J. Neurophysiol. 88, 1387–
1392.
Zhang, Y.H., Vasko, M.R., and Nicol, G.D. (2002b). Ceramide, a puta-
tive second messenger for nerve growth factor, modulates the TTX-
resistant Na(+) current and delayed rectifier K(+) current in rat sensory
neurons. J. Physiol. 544, 385–402.
